Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Christopher D.M. Fletcher, M.D., M.B.,B.S.

Co-Author

This page shows the publications co-authored by Christopher Fletcher and George Demetri.
Connection Strength

2.657
  1. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-2004. A 68-year-old man with a large retroperitoneal mass. N Engl J Med. 2004 Oct 21; 351(17):1779-87.
    View in: PubMed
    Score: 0.308
  2. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res. 2009 Sep 15; 15(18):5902-9.
    View in: PubMed
    Score: 0.108
  3. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008 Nov 20; 26(33):5352-9.
    View in: PubMed
    Score: 0.102
  4. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5398-405.
    View in: PubMed
    Score: 0.094
  5. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007 Jul; 5 Suppl 2:S1-29; quiz S30.
    View in: PubMed
    Score: 0.093
  6. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006 Oct 14; 368(9544):1329-38.
    View in: PubMed
    Score: 0.088
  7. Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9502.
    View in: PubMed
    Score: 0.086
  8. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol. 2005 Jun; 23(16_suppl):9011.
    View in: PubMed
    Score: 0.080
  9. Clinical benefit of imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trial. J Clin Oncol. 2005 Jun; 23(16_suppl):9010.
    View in: PubMed
    Score: 0.080
  10. Liposarcoma subtypes: identification with computed tomography and ultrasound-guided percutaneous needle biopsy. Eur Radiol. 2005 Feb; 15(2):383-9.
    View in: PubMed
    Score: 0.077
  11. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res. 2004 Sep 01; 10(17):5732-40.
    View in: PubMed
    Score: 0.076
  12. Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3010.
    View in: PubMed
    Score: 0.076
  13. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3001.
    View in: PubMed
    Score: 0.076
  14. NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2004 May; 2 Suppl 1:S-1-26; quiz 27-30.
    View in: PubMed
    Score: 0.075
  15. Current management of metastatic gastrointestinal stromal tumor: a case report. Clin Adv Hematol Oncol. 2003 Jan; 1(1):63-4; discussion 65.
    View in: PubMed
    Score: 0.068
  16. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 2002 Nov; 3(11):655-64.
    View in: PubMed
    Score: 0.067
  17. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15; 347(7):472-80.
    View in: PubMed
    Score: 0.066
  18. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001 Aug 16; 20(36):5054-8.
    View in: PubMed
    Score: 0.062
  19. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021 Aug 15; 127(16):2934-2942.
    View in: PubMed
    Score: 0.060
  20. Malignant epithelioid angiomyolipoma ('sarcoma ex angiomyolipoma') of the kidney: a case report and review of the literature. Am J Surg Pathol. 2001 Jan; 25(1):121-6.
    View in: PubMed
    Score: 0.059
  21. Management of soft-tissue sarcomas: an overview and update. Lancet Oncol. 2000 Oct; 1:75-85.
    View in: PubMed
    Score: 0.058
  22. Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma. Cancer. 1999 Oct 15; 86(8):1621-7.
    View in: PubMed
    Score: 0.054
  23. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999 Mar 30; 96(7):3951-6.
    View in: PubMed
    Score: 0.052
  24. c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas. J Pathol. 2014 Oct; 234(2):190-202.
    View in: PubMed
    Score: 0.038
  25. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet. 2014 Jun; 46(6):601-6.
    View in: PubMed
    Score: 0.037
  26. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19; 379(9829):1879-86.
    View in: PubMed
    Score: 0.033
  27. Aberrant AKT activation drives well-differentiated liposarcoma. Proc Natl Acad Sci U S A. 2011 Sep 27; 108(39):16386-91.
    View in: PubMed
    Score: 0.031
  28. High rates of histopathologic discordance in sarcoma with implications for clinical care. J Clin Oncol. 2011 May 20; 29(15_suppl):10065.
    View in: PubMed
    Score: 0.030
  29. Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. Arch Pathol Lab Med. 2010 Feb; 134(2):165-70.
    View in: PubMed
    Score: 0.028
  30. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010 Feb 10; 28(5):835-40.
    View in: PubMed
    Score: 0.028
  31. Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol. 2010 Feb; 17(2):407-15.
    View in: PubMed
    Score: 0.027
  32. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer. 2009 Nov; 45(16):2818-24.
    View in: PubMed
    Score: 0.027
  33. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008 Nov 20; 26(33):5360-7.
    View in: PubMed
    Score: 0.025
  34. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008 Sep; 216(1):64-74.
    View in: PubMed
    Score: 0.025
  35. Multimodality treatment of mesenteric desmoid tumours. Eur J Cancer. 2008 Nov; 44(16):2404-10.
    View in: PubMed
    Score: 0.025
  36. Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors. Oncogene. 2008 Sep 18; 27(42):5624-34.
    View in: PubMed
    Score: 0.025
  37. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008 Feb 01; 26(4):620-5.
    View in: PubMed
    Score: 0.024
  38. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008 Feb 01; 26(4):626-32.
    View in: PubMed
    Score: 0.024
  39. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance. Oncogene. 2007 Sep 27; 26(44):6386-95.
    View in: PubMed
    Score: 0.023
  40. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006 Oct 10; 24(29):4764-74.
    View in: PubMed
    Score: 0.022
  41. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006 May 20; 24(15):2325-31.
    View in: PubMed
    Score: 0.021
  42. Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res. 2004 Aug 01; 64(15):5127-31.
    View in: PubMed
    Score: 0.019
  43. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033. J Clin Oncol. 2004 Jul 15; 22(14_suppl):9005.
    View in: PubMed
    Score: 0.019
  44. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene. 2004 May 13; 23(22):3999-4006.
    View in: PubMed
    Score: 0.019
  45. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003 Dec 01; 21(23):4342-9.
    View in: PubMed
    Score: 0.018
  46. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res. 2003 Jun; 9(6):1941-56.
    View in: PubMed
    Score: 0.017
  47. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003 Jan 31; 299(5607):708-10.
    View in: PubMed
    Score: 0.017
  48. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. 2002 Sep 15; 20(18):3898-905.
    View in: PubMed
    Score: 0.017
  49. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001 Nov 15; 61(22):8118-21.
    View in: PubMed
    Score: 0.016
  50. Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Ann Surg. 2001 Aug; 234(2):215-23.
    View in: PubMed
    Score: 0.015
  51. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol. 2000 Mar; 156(3):791-5.
    View in: PubMed
    Score: 0.014
  52. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol. 1999 Oct; 17(10):3252-9.
    View in: PubMed
    Score: 0.014
  53. Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome. Ann Surg. 1999 Jul; 230(1):79-86.
    View in: PubMed
    Score: 0.013
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.